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Abstract
Background: A key aspect of randomized trial design is the choice of risk group. Some trials
include patients from the entire at-risk population, others accrue only patients deemed to be at
increased risk. We present a simple statistical approach for choosing between these approaches.
The method is easily adapted to determine which of several competing definitions of high risk is
optimal.
Method: We treat eligibility criteria for a trial, such as a smoking history, as a prediction rule
associated with a certain sensitivity (the number of patients who have the event and who are
classified as high risk divided by the total number patients who have an event) and specificity (the
number of patients who do not have an event and who do not meet criteria for high risk divided
by the total number of patients who do not have an event). We then derive simple formulae to
determine the proportion of patients receiving intervention, and the proportion who experience
an event, where either all patients or only those at high risk are treated. We assume that the
relative risk associated with intervention is the same over all choices of risk group. The proportion
of events and interventions are combined using a net benefit approach and net benefit compared
between strategies.
Results: We applied our method to design a trial of adjuvant therapy after prostatectomy. We
were able to demonstrate that treating a high risk group was superior to treating all patients;
choose the optimal definition of high risk; test the robustness of our results by sensitivity analysis.
Our results had a ready clinical interpretation that could immediately aid trial design.
Conclusion: The choice of risk group in randomized trials is usually based on rather informal
methods. Our simple method demonstrates that this decision can be informed by simple statistical
analyses.
Background
Protocols of randomized trials specify inclusion and
exclusion criteria to determine the population under
study. Exclusion criteria typically focus on identifying sub-
jects who might be harmed by the study intervention,
those for whom benefit is doubtful and those who are
unlikely to provide useful data. Inclusion criteria tend to
focus on risk: all trials identify the population at risk for
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the study event, some trials additionally specify criteria to
define a study population at high-risk. For example, a trial
comparing recurrence rates between two approaches to
prostatectomy will specify only that patients with local-
ized prostate cancer are eligible; a trial to determine the
effects of adjuvant therapy might further restrict eligibility
to patients with locally advanced cancer who are at high
risk of recurrence. In some cases trialists studying a similar
question have reached different conclusions as to whether
to include the whole at-risk population or only a high-risk
subgroup. The PLCO trial, for instance, includes all older
individuals in a study of lung cancer screening [1],
whereas the National Lung Screening Trial[2] includes
only smokers, or recent quitters, with a smoking history of
30 pack-years or more.
In this paper, we present a simple statistical approach for
determining whether trialists should use a "whole popu-
lation" or "high-risk group" approach. The results of the
method have a ready clinical interpretation that can
immediately aid trial design, moreover, the method is eas-
ily adapted to determine which of several competing def-
initions of high-risk is optimal. In a previous paper, which
focused on screening and prevention, two of us argued
that the population accrued to a trial should be the same
as that to whom the intervention will be applied in prac-
tice[3]. Thus the decision whether to include all members
of an eligible population, or just a high-risk sub-group,
should depend on the relative benefit of these alternative
strategies were they to be clinically applied after the com-
pletion of a trial indicating an effect of the intervention.
We therefore model benefits of alternative strategies in a
hypothetical population in order to determine the opti-
mal approach.
Method
Our method is based on the assumption that interven-
tions proven in randomized trials will be offered to eligi-
ble patients similar to those studied in the trial. For
example, we assume that if a trial accruing patients with
locally advanced prostate cancer demonstrates effective-
ness of adjuvant therapy, such treatment will subse-
quently be offered to patients with locally advanced but
not organ-confined disease. We therefore compare the
predicted outcome of treating all at-risk patients in the
population at large to the outcome of treating only the
high-risk subgroup. We then recommend the approach
with the better outcome to determine the inclusion crite-
ria for the randomized trial.
Outcome is defined in terms of "net benefit" in the eligi-
ble population. Net benefit is a concept often used in eco-
nomic analysis and is simply benefits minus harms. In the
case of a medical intervention, "benefits" are associated
with reduction in the event rate compared to no addi-
tional treatment: in an adjuvant therapy trial, for instance,
benefit would be a reduction in cancer recurrences or
deaths compared to surgery alone. "Harms" are associated
with the intervention itself: side-effects, costs, inconven-
ience and so on. To assess the relative outcome of the
whole population and high-risk approach, we therefore
need to calculate the proportion of patients who would be
treated, and the reduction in event rate, for each approach.
For the whole population approach this is straightfor-
ward: the proportion of patients treated is 100% and the
reduction in event rate is simply the event rate in the
absence of intervention multiplied by the anticipated rel-
ative risk of the event with versus without intervention.
To determine intervention and event rates for the
approach of treating only high-risk patients, consider that
an investigator proposing a trial on high-risk patients
must propose specific criteria to determine high-risk. This
might involve a single risk factor (e.g. non-organ confined
disease) or a threshold probability on a multivariable pre-
diction model (or "nomogram") including a variety of
risk factors (e.g. stage, grade, PSA [4]). Such criteria can be
seen as a prediction tool: individuals who meet the criteria
are thought to be more likely to experience a disease-
related event than those who do not meet the criteria. We
can then calculate the sensitivity and specificity of this
prediction tool. To define "sensitivity" we use as the
numerator the number of individuals in the eligible pop-
ulation who both have the event (in the absence of inter-
vention) and who are classified as high risk; the
denominator is the total number of patients who have the
event. "Specificity" is comparably defined by using for the
numerator the number of individuals in the eligible pop-
ulation who do not have the event and who do not meet
the criteria for high risk; the denominator is the total
number who do not have the event (see table 1 for illus-
trative data). Data on sensitivity, specificity and event rate
may be obtained from epidemiologic data sets or from
analyzing the control arm of prior randomized trials.
Table 1: Relationship between criteria for defining a "high-risk" 
sub-group and whether a patient has an event during a clinical 
trial.
Event?
Yes No
Meet criteria for "high-risk"? Yes 396 624
No 632 3,799
Hypothetical data are given for the purposes of illustration.
Sensitivity = 396 ÷ (396+632) = 39%
Specificity = 3799 ÷ (624+3799) = 86%Trials 2006, 7:30 http://www.trialsjournal.com/content/7/1/30
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In the Appendix [see Additional file 1], we derive the fol-
lowing formulae for the intervention and event rates
when selecting a high-risk group.
Intervention rate: the anticipated proportion of eligible
population receiving intervention when the intervention
is given only to high risk subjects
= Event rate in the absence of intervention × sensitivity +
(1 – Event rate in the absence of intervention) × (1 – spe-
cificity)
Event rate: the anticipated proportion of eligible popula-
tion who have the event when intervention given to the
high risk group:
= Event rate in the absence of intervention × sensitivity ×
relative risk + Event rate in the absence of intervention ×
(1 – sensitivity)
Decrease in event rate due to intervention:
= Event rate in the absence of intervention – Event rate
when intervention given to high risk group
Where:
Event: a negative medical outcome such as disease recur-
rence or death occurring within the projected time frame
of the trial
Event rate in the absence of intervention: expected pro-
portion of individuals in the eligible population who will
have the event
Sensitivity: numerator: number of individuals in the eli-
gible population who both have the event (in the absence
of intervention) and who are classified as high risk;
denominator: the total number of patients who have the
event.
Specificity: numerator: number of individuals in the eli-
gible population who do not have the event and who do
not meet the criteria for high risk; denominator: total
number who do not have the event.
Relative risk: relative risk of the event with versus without
intervention
As described above, net benefit is benefit minus harm,
where benefit is related to the number of events and harm
to the number of interventions. To formulate net benefit
precisely, it is necessary to put benefits and harms on the
same scale. The problem is that events and interventions
are not equivalent: an event, such as a prostate cancer
recurrence, is generally considered worse than an inter-
vention, such as adjuvant therapy. Just how much worse
an event is considered than an intervention will vary from
case to case. A common way of converting between events
and interventionsis the "number-needed-to-treat" (NNT).
We define the threshold NNT (NNTt) as the maximum
number of patients that a clinician would treat to prevent
one event. The NNTt may be based on an informal subjec-
tive judgment; alternatively, methods have been described
in the literature to derive NNTt based on the relative harm
associated with intervention and an event[5]. NNTt can be
thought of in economic terms as the amount we would
pay, in interventions, to avoid one event. As such, NNTt is
independent of the event rate. Hence we define:
Net benefit = decrease in event rate – intervention rate ÷
NNTt
Note that the units of the left and right terms in the net
benefit equation are the same: NNTt is in units of interven-
tion rate divided by event rate, so the units are in terms of
event rates.
We propose calculating net benefit for the strategy of treat-
ing all patients and for treating only the high-risk group.
The approach with the highest net benefit in the eligible
population after completion of the trial is chosen for trial
design.
Illustrative example
A group of investigators wish to investigate whether adju-
vant therapy can reduce the risk of recurrence after radical
prostatectomy. They plan to randomize patients to sur-
gery alone or surgery with hormonal therapy and follow
patients for five years to determine the proportion who
recur. About 20% of all prostatectomy patients recur
within 5 years (i.e. the event rate in the absence of inter-
vention) and the expected effect of adjuvant therapy is a
relative risk of 0.75. Discussion with clinicians and
patients suggest an NNTt of 100 for prostate cancer death,
that is, if 100 or fewer patients had to be treated with adju-
vant therapy to prevent one death, it would be considered
worth taking; if more than 100 had to take the agent to
prevent one death, the costs, side-effects, risks and incon-
venience of the drug would be seen to outweigh its bene-
fits. As only approximately one in three patients who recur
after prostatectomy die from disease, the NNTt for the
study endpoint of recurrence is 33.
The standard predictive model for prostate cancer recur-
rence is the "Kattan nomogram" and this has been used in
several randomized trials to determine eligibility. Trials
have varied as to the threshold risk of recurrence used to
determine eligibility: 40% for NCT00283062, 50% for
NCT00132301 and 25% for NCT00258765. Let us imag-Trials 2006, 7:30 http://www.trialsjournal.com/content/7/1/30
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ine that our group of investigators disagree as to the opti-
mal threshold: whilst one investigator wishes to define
patients as "high risk" if they have 50% or greater risk of
recurrence, another argues that the threshold should be
set much lower, at 10%, in order to ensure that most
patients who actually do recur would be eligible. Mean-
while, the drug company argues that prostate cancer is an
unpredictable disease and that the investigators should
keep an open mind about whether to accrue all prostatec-
tomy patients to the trial. Note that although the Kattan
nomogram is a multivariate model, this is not a require-
ment of our approach: eligibility criteria can be deter-
mined by a model, by a single risk factor – such as a
smoking history of at least 30 pack-years – or a combina-
tion of risk factors, such as including patients with either
high stage cancer or a positive surgical margin.
We obtained from the author data on the sensitivity and
specificity of the Kattan nomogram at various cut-points.
Table 2 gives the intervention rate, event rate, decrease in
event rate from intervention and the net benefit for both
the different high-risk categories and the strategy of treat-
ing all patients. Note that the event rate is not that
observed in the trial, but that in the population as a
whole, were the intervention to be applied in practice.
As a worked example, we will look at the strategy of treat-
ing only patients with a risk of 50% or more. The formula
for the intervention rate is: Event rate in the absence of
intervention × sensitivity + (1 – Event rate in the absence
of intervention) × (1 – specificity), i.e., 20% × 47% + 80%
× 4% = 12.6%. The formula for the event rate after the
intervention is applied to high-risk subjects is: Event rate
in the absence of intervention × sensitivity × relative risk +
Event rate in the absence of intervention × (1 – sensitivity)
or 20% × 47% × 0.75 + 20% × 53% = 17.65%. This is a
decrease is event rate of 20% – 17.65% = 2.35%. The for-
mula for net benefit is decrease in event rate – interven-
tion rate ÷ NNTt giving 2.35% – 12.60% ÷ 33 = 0.01968
as the net benefit for the strategy of treating only men with
a risk of 50% or more.
From the table, we can see that the highest net benefit is
associated with treating only men with a nomogram pre-
dicted risk of recurrence of 10% or more. We would rec-
ommend using this as the eligibility criteria for the trial.
One particular advantage of our approach is that net ben-
efit has a simple clinical interpretation in terms of either a
decrease in event rate while keeping the intervention rate
constant or a decrease in the intervention rate while keep-
ing the event rate constant. For example, the net benefit
for the high-risk group is 0.0296 greater than that of not
using adjuvant therapy in any patient. Thus the strategy of
calculating a prediction for all patients and administering
an intervention to those with a predicted risk of recur-
rence ≥ 10% gives the same net benefit as a strategy (say,
a change in surgical technique) that leads to the equiva-
lent of about 3 fewer recurrences per 100 patients without
any patients receiving adjuvant therapy. A similar calcula-
tion can be conducted to determine the decrease in inter-
vention rate for a constant event rate: in this case, the
difference in net benefit is multiplied by the NNTt.
Sensitivity analysis
Any of the inputs required to calculate net benefit can be
varied to determine whether this affects which strategy is
deemed optimal. The event rate in the absence of the
study intervention can usually be estimated (e.g. from
cohort studies), and whether it is worth varying sensitivity
and specificity will depend on the size and quality of the
studies used to estimate these parameters. Hence the two
most important sensitivity analyses concern NNTt – on
the grounds that this is a judgment that can reasonably
vary from individual to individual and place to place –
and relative risk, on the grounds that this is unknown dur-
ing trial planning.
Figure 1 shows the optimal strategy for different combina-
tions of NNTt and relative risk. In accordance with intui-
tion, figure 1 shows that the more effective and tolerable
the intervention, the more likely we are to selecting inter-
vening in all patients rather than just a high-risk group;
the less effective and tolerable the intervention, the more
likely we are to chose to treat only a high-risk group, or
Table 2: Calculations to determine whether to treat the whole population or just a high-risk group.
Strategy Sensitivity Specificity Intervention rate Event rate Decrease in 
event rate 
(benefit)
Net benefit (benefit – 
intervention rate ÷ 
NNTt)
Treat none 0% 100% 0.0% 20.00% 0% 0
Treat high-risk (risk 10% +) 91% 57% 52.60% 15.45% 4.55% 0.02956
Treat high-risk (risk 50% +) 47% 96% 12.60% 17.65% 2.35% 0.01968
Treat all 100% 0% 100.0% 15.00% 5.00% 0.01970
The relative risk of the intervention is 0.75, the NNTt is 33 and the event rate in the absence of intervention is 20%. The decrease in event rate is 
the event rate in the population in the absence of intervention minus the event rate in the population when individuals meeting the high-risk 
definition receive intervention.Trials 2006, 7:30 http://www.trialsjournal.com/content/7/1/30
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no-one at all. Let us imagine that one investigator is of the
opinion that interventions are rarely as effective or tolera-
ble as hoped. If we reduce relative risk or NNTt from the
base scenario of 0.75 and 33, we sometimes choose a cut-
off of 10% and other times a cut-off of 50%. The investi-
gator therefore suggests examining a cut-off of 25% to
define high-risk. This is associated with a sensitivity of
72% and a specificity of 84%. The net benefit for this def-
inition of high-risk is shown in table 3 for various combi-
nations of NNTt and relative risk. The new definition is
superior for most scenarios. The investigators decide to
run the trial using a predicted risk of recurrence of at least
25% as the inclusion criterion for the trial.
Our method assumes that, following a positive trial result,
all or nearly all high risk patients will receive the interven-
tion, and none, or nearly none, of the low risk population
will be treated. This might be seen as a somewhat unreal-
istic ideal of evidence-based medical practice. However, it
is easy to adjust estimates of event rates and intervention
rates in the presence of variation from this standard by
specifying a proportion of high risk patients are not
treated and a proportion of low risk patients who inap-
propriately receive intervention (see Appendix [Addi-
tional file 1] for formulae).
Applying the method to other sample scenarios
In tables 4 and 5, we create a number of different scenar-
ios to illustrate the circumstances in which it is preferable
to select a high-risk group for intervention. Table 4 shows
that the value of selecting a high-risk group, in compari-
son to the whole population approach, is greater as the
event rate decreases. In table 5, the value of selecting high-
risk patients is associated with lower tolerability or lesser
effectiveness of the intervention. If an intervention is
either very effective or highly tolerable, the high-risk
approach is only of benefit if selection criteria are highly
sensitive, in other words, in the case that nearly all those
who could benefit from the intervention receive it. Con-
versely, if the effectiveness of the intervention is moderate,
or it is poorly tolerated, selection criteria must be specific,
that is, only those patients who would benefit are selected.
These considerations suggest that focusing on a high-risk
group might be of particular value for screening or preven-
tion trials, as these typically involve low event rates, inter-
ventions of moderate effectiveness and a population with
a low tolerance for adverse treatment effects.
The final two rows of table 5 demonstrate the value of a
decision analytic approach to the problem of risk group
selection. In one scenario, selection criteria that have near
perfect sensitivity and specificity are useless because the
intervention is highly effective and tolerable, and there-
fore there is little downside to treating all patients. In
another scenario, selection criteria that are only margin-
ally better than random guessing should be used to select
a high-risk group because intervening is of extremely mar-
ginal benefit.
Sample size considerations
We can derive additional simple formulae to help deter-
mine sample size (see Appendix [Additional file 1]). The
proportion of events in the control arm of the trial is: sen-
sitivity × event rate in the absence of intervention ÷ inter-
vention rate. This number can be entered into a standard
sample size calculation for a difference between propor-
tions. We can then calculate the number of patients that
need to be screened as number of patients in trial ÷ inter-
vention rate. Table 6 gives number of patients in a trial
and number to be screened where sample size is calcu-
lated assuming a 25% risk reduction from intervention.
Sample size varies considerably between samples,
although the number of patients who would need to be
screened is reasonably constant. As a worked example, we
will look at the first row, the strategy of including all
patients with a risk of recurrence of 50% or more. The cal-
culation for the intervention rate has already been
described above. The formula for the event rate in the con-
trol group of the trial is: sensitivity × event rate in the
absence of intervention ÷ intervention rate, i.e. 47% (from
table 2) × 20% ÷ 12.6% = 74.6%. To calculate the event
rate in the treatment arm, this is multiplied by the relative
risk, i.e. 74.6% × 0.75 = 55.95%. Using the sampsi func-
tion on Stata 9.2 (Stata Corp., College Station, Texas), a
Sensitivity analysis for a prostate cancer adjuvant trial Figure 1
Sensitivity analysis for a prostate cancer adjuvant trial. The 
shaded areas identify the optimal strategy for each combina-
tion of NNTt and relative risk. White: include whole at-risk 
population of men undergoing prostatectomy. Dark grey: 
Include men with a predicted probability of recurrence ≥ 
10% ; Light grey: Include men with a predicted probability of 
recurrence ≥ 50%; Black: Include no men on the trial (inter-
vention does more harm than good). Note that specificity of 
the optimal strategy increases from top left to bottom right.Trials 2006, 7:30 http://www.trialsjournal.com/content/7/1/30
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trial with 90% power to detect a difference at a signifi-
cance level of 5% between an event rate of 74.6% and
55.95% requires 292 patients. As we include 12.6% of
patients on trial (the intervention rate) to obtain 292
patients we would have to screen 292 ÷ 12.6% = 2317.
The general approach we suggest is only based on net ben-
efit in the eligible population after completion of the trial,
and does not take into account the sample size considera-
tions. If there is an upper bound on the sample size due to
budget constraints, the risk group selected should be that
group with highest net benefit among those under consid-
eration that satisfy the budget for the trial. Alternatively,
one could consider a more complex calculation of net
benefit subject to a constraint on total trial costs[6].
Discussion
Determining who should receive an intervention is a key
aspect of medical practice. It is inevitable that, although
some interventions should be applied to all members of
an at-risk population (e.g. antibiotics before surgery), oth-
ers should be restricted to those at high-risk (e.g. β-block-
ers before surgery). To our knowledge, no previous
investigators have described a simple strategy for deter-
mining whether a trial should accrue patients selected
from the whole at-risk population or only to those from a
high-risk subgroup. Moreover, criteria for determining the
appropriate definition of high-risk subgroup have not
been developed systematically, for example, by quantita-
tively comparing different definitions.
Accordingly, prior approaches to issues of patient selec-
tion in randomized trials have been rather informal. For
example, at a National Cancer Institute workshop on risk
prediction models, it was reported that participants
"repeatedly discussed the use of cancer risk prediction
models for high-risk versus population approaches to can-
cer prevention". Yet the only guidance given was that a
population prevention strategy would be optimal unless a
predictive model had "high discriminatory power" to
Table 4: Net benefit for treating high-risk and all patients, varying the event rate in the absence of intervention.
Event rate in the absence of intervention Net benefit (high-risk) Net benefit (treat all) Net benefit compared to treat all
50% 0.09713 0.12000 -0.02288
10% 0.01803 0.02000 -0.00198
7.5% 0.01308 0.01375 -0.00067
5% 0.00814 0.00750 0.00064
2.5% 0.00319 0.00125 0.00194
1% 0.00023 -0.00250 0.00273
Results are for a scenario where relative risk = 0.75; sensitivity = 80%; specificity = 65% and NNTt = 200
Table 3: Sensitivity analysis. Net benefit when relative risk and NNTt are varied.
Relative Risk
NNTt Cut-off for risk of recurrence 0.75 0.8 0.85 0.9
10 10% -0.00710 -0.0162 -0.02530 -0.03440
25% 0.00880 0.00160 -0.00560 -0.01280
50% 0.01090 0.00620 0.00150 -0.00320
15 10% 0.01043 0.00133 -0.00777 -0.01687
25% 0.01787 0.01067 0.00347 -0.00373
50% 0.01510 0.01040 0.00570 0.00100
20 10% 0.01920 0.01010 0.00100 -0.00810
25% 0.02240 0.01520 0.00800 0.00080
50% 0.01720 0.01250 0.00780 0.00310
25 10% 0.02446 0.01536 0.00626 -0.00284
25% 0.02512 0.01792 0.01072 0.00352
50% 0.01846 0.01376 0.00906 0.00436
33 10% 0.02956 0.02046 0.01136 0.00226
25% 0.02776 0.02056 0.01336 0.00616
50% 0.01968 0.01498 0.01028 0.00558
The relative risk of the intervention is 0.75, the NNTt is 33 and the event rate in the absence of intervention is 20%. The decrease in event rate is 
the event rate in the population in the absence of intervention minus the event rate in the population when individuals meeting the high-risk 
definition receive intervention.Trials 2006, 7:30 http://www.trialsjournal.com/content/7/1/30
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identify those who will develop a disease[7]. This begs the
question of just how good a model has to be, and omits
what we have demonstrated to be the key variables of the
underlying event rate, intervention effectiveness and toler-
ability.
A debate concerning the inclusion criteria for the National
Lung Screening Trial is similarly illustrative. In the origi-
nal trial protocol, the investigators set inclusion criteria of
a 30 pack-year or greater smoking history and no more
than 15 years since quitting[2]. No clear rationale was
given for this threshold. Subsequently, a separate group of
investigators created a risk prediction model for lung can-
cer and argued that, because its predictive properties were
well understood, this might be used to select patients for
a clinical trial[2]. However, these investigators did not
demonstrate clearly that any specific set of criteria derived
from their model was superior to those used in the trial.
Given the apparent advantages of our method, we should
discuss some of its limitations. One important assump-
tion of the method is that the relative risk for intervention
versus no intervention is constant over the choice of risk
groups. Generally speaking, we do not know whether this
is true: indeed, two of us have previously used possible
inconstancy of relative risk to argue against accruing only
high-risk patients and then applying the results to the
whole eligible population[3]. However, we think there is
an important difference between using a certain assump-
tion to help design a trial and using it to make a clinical
decision. In case of a clinical decision about treatment,
patients could be harmed if assumptions about relative
risk do not hold. We would therefore like to avoid any
such assumptions. In the case of trial design, any design
we choose necessarily involves assumptions, explicit or
otherwise, about the relationship between relative and
absolute risk. Moreover, these assumptions can be tested
once the trial is completed and further research recom-
mended if appropriate.
An apparent disadvantage of our method is that it
involves a subjective judgment of NNTt, and a prediction
as to relative risk. However, these would be needed for
other design decisions even if an investigator chose not to
follow our recommendations. For example, the NNTt is
equivalent to the "minimum clinically significant differ-
ence" that is used in standard sample size calculations;
predictions as to event rates are similarly part-and-parcel
of sample size estimation.
An alternative to the approach suggested here would be to
conduct a trial including all patients, use the trial data to
build a predictive model and then select a high-risk group
accordingly. The principal advantage is that we can model
treatment benefit, rather than baseline risk, and therefore
do not need to make assumptions about a constant rela-
Table 6: Sample size requirements for different scenarios. Sample size is calculated using 90% power and 5% alpha
Strategy Intervention 
rate
Event rate in control arm of trial Sample size (pts. screened) for relative risk of 0.75
Treat high-risk (risk 10% +) 52.60% 34.6% 1228 (2335)
Treat high-risk (risk 25% +) 27.20% 52.9% 624 (2294)
Treat high-risk (risk 50% +) 12.60% 74.6% 292 (2317)
Treat all 100.00% 20.0% 2504 (2504)
Table 5: Net benefit for treating high-risk and all patients, varying the effectiveness and tolerability of intervention.
Scenario Relative 
Risk
NNTt Sensitivity Specificity Net benefit 
(high-risk)
Net benefit 
(treat all)
Net benefit: 
high-risk – 
treat all
Effective intervention 0.50 100 40% 80% 0.00790 0.01500 -0.00710
Effective intervention, high sensitivity 0.50 100 95% 45% 0.01805 0.01500 0.00305
Highly tolerable intervention 0.75 500 40% 80% 0.00458 0.01050 -0.00592
Highly tolerable intervention, high 
sensitivity
0.75 500 95% 40% 0.01064 0.01050 0.00014
Adverse intervention 0.75 40 40% 80% -0.00025 -0.01250 -
Adverse intervention, high specificity 0.75 40 30% 90% 0.00100 -0.01250 0.01350
The ideal intervention, high sensitivity and 
specificity
0.25 500 95% 90% 0.03534 0.03550 -0.00016
Questionable intervention, poor sensitivity 
and specificity
0.80 100 51% 51% 0.00019 0.00000 0.00019
The event rate in the absence of intervention is 5% for all scenarios.Trials 2006, 7:30 http://www.trialsjournal.com/content/7/1/30
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tive risk. This approach has been pioneered successfully
with respect to adjuvant chemotherapy[8]. However, in
practice, clinicians and statisticians are uncomfortable
recommending interventions to sub-groups of patients
unless these have demonstrated clinical and statistical sig-
nificance in the primary analysis of a randomized trial. It
is quite plausible that an intervention with a modest effect
size, or one targeting a moderately prevalent disease, will
not show sufficient overall effectiveness in definitive trial
and will be dropped from consideration, even though it
would be of important benefit to a sub-group of high-risk
patients. An illustrative recent example is the Women's
Health Initiative study of calcium and vitamin D for frac-
ture prevention. Overall, this study found rather small
benefits of supplementation[9], the key conclusion being
that treatment "did not significantly reduce hip fracture".
Many of the women in this study were at very low risk: for
example, 37% of the participants were aged 50 to 59 and
the rate of fracture in this sub-group was only about 0.3%.
It is entirely possible that supplementation is of impor-
tant benefit for older women at higher risk of fracture, but
that the use of supplementation in the community will
decline given the rather negative overall study results.
In this paper, we have introduced a statistical method to
determine whether or not to restrict a study to a high-risk
population and, if so, to determine which of several com-
peting definitions of high-risk is optimal. Our method is
simple and produces results with direct clinical applicabil-
ity. It should appeal to clinicians since the quantitative
results are in concert with clinical intuition. However, we
feel that the mathematical details of our method are per-
haps less important than our overall message, which
includes four main points. First, it may be more rational
to focus on high-risk groups than to treat everyone at risk.
Second, whether or not to restrict an intervention to a
high-risk group is a question that can be informed by data
and statistical analyses. It is our impression that current
decisions about whom to include in trials have not been
statistically based, rather, they appear to have depended
on informal judgment. Third, trial eligibility criteria in tri-
als that attempt to identify high-risk subjects (such as pack
years in a lung cancer screening trial) can be seen as pre-
dictions with certain statistical properties. We have chosen
to describe these in terms of sensitivity and specificity, on
the grounds that these terms are readily understood by
most clinicians. Fourth, we can compare different
approaches to trial eligibility using formal statistical anal-
ysis. We believe that a more systematic approach to
patient selection will maximize the benefits of rand-
omized trials for human health.
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